Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 85.8%

Neg 0% Neu 0% Pos 85.8%

Citigroup analyst Joanne Wuensch maintains Minimed Group (NASDAQ:MMED) with a Buy and raises the price target from $23 to $26.